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Evidence that the survival of women with breast cancer treated by specialist surgeons is better than that by nonspecialists is limited.
Previous reports have not identified the cause of this survival advantage. Our aim was to determine if the survival difference was due
to case-mix, adjuvant treatment or the treatment provided by specialist surgeons. The case-records and pathology reports of 2776
women were reviewed. This represented 95% of all those diagnosed with breast cancer between 1/1/1986 and 31/12/1991 in a
defined geographical area. Case-mix, surgery, pathology and adjuvant therapies of the 2148 women treated with curative intent were
analysed. A standard of adequate surgical management was defined and confirmed as a valid predictor by examining rates of local
recurrence, independent of all other prognostic factors. Against this standard, we compared the adequacy of surgical management,
local recurrence rates and the survival outcomes of specialists and nonspecialists over an 8-year follow-up period. The inter-
relationship between adequacy of surgical management, locoregional recurrence and survival was examined. While the case-mix and
prescription of adjuvant therapies were comparable between specialist and nonspecialist surgeons, the efficacy and outcome of local
treatment differed widely. Breast cancer patients treated in specialist compared to nonspecialist units had half the risk of inadequate
treatment of the breast (24 vs 47%, Po0.001), a five-fold lower risk of inadequate axillary staging (8 vs 40%, Po0.001) and nine times
lower risk of inadequate definitive axillary treatment (4 vs 38%, Po0.001). Local recurrence rates were 57% lower (13 vs 23% at eight
years, Po0.001) and the risk of death from breast cancer was 20% lower for women treated in specialist units, after allowing for case-
mix and adjuvant therapies. Adequacy of surgical management correlated with locoregional recurrence, which in turn correlated with
the risk of death. The surgical management in specialised breast units is more often adequate, local and regional recurrence rates are
lower, and survival is correspondingly better. We conclude that adequate surgical management of breast cancer is fundamental to
improving the outcome from breast cancer irrespective of where it is delivered.
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Cancer services in the UK increasingly involve specialisation,
particularly in the treatment of breast cancer. Specialisation has
been shown to be associated with an improvement in survival from
breast cancer on a population basis but the nature of this has
remained unclear (Gillis and Hole, 1996). Reasons for this lack of
evidence include incomplete data on case-mix, treatment mod-
alities and outcomes. Other studies that have similarly reported a
survival advantage to treatment in larger centres could not fully
account for this (Sainsbury et al, 1995a).
This study compares the surgical management provided by
specialist and nonspecialist surgeons, the adequacy of manage-
ment in relation to a guideline relevant to the study period, and
their outcomes after adjustment for case-mix. The hypothesis
tested is that specialist units provide better local control and that
this improves survival.
METHODS
Identification of cases
The records of the West of Scotland Cancer Registry were used to
identify all women aged under 75 years diagnosed between 1
January 1986 and 31 December 1991 with a histologically
confirmed invasive breast cancer in the same defined geographical
area, population 1.2 million, used in the previous study (Gillis and
Hole, 1996). This time period was chosen to ensure good case-
record availability with adequate follow-up to demonstrate
survival differences. In addition, the implementation of the NHS
Breast Screening Programme in the study area will have altered
referral patterns and management after 1991. The publication of
the Kings’ Fund Consensus Statement (King’s Fund Forum
Consensus Statement, 1986) in 1986 provided a good time-specific
standard of treatment. For the 6-year period studied, 2934 women
were treated for breast cancer in nine different hospitals by 54
consultant surgeons. The medical records and pathology reports of
2776 women (95% of the total) were reviewed. Excluded from the
study were 72 women who had screen-detected tumours and 556
women not primarily treated with curative surgery leaving 2148
women as the basis of this study of treatment and outcome.
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Permission to access the medical records was granted by all
consultants who treated breast cancer in the participating hospitals
at that time. A higher surgical trainee with experience of treating
breast cancer collected data from the following sources; in-patient
records, operation notes, pathology reports, original death
certificates and the case-records of the regional centre for
oncology, from which all radiotherapy and chemotherapy was
given. This provided information on each step of the complete
process of care including case-mix, diagnostic procedures,
operative procedures, pathological details, adjuvant therapies,
recurrence and death.
Histological grading was not reported in all hospitals during the
time period of this study. Therefore, tumours were classified into
histological prognostic groups based on type and grade where
mentioned: good prognosis (ductal grade I, well differentiated and
special types e.g. tubular), moderate prognosis (ductal grade II, no
comment, or lobular) and poor prognosis (poorly differentiated or
ductal grade III). Multivariate analysis of recurrence and survival
confirmed these groupings as valid, independent of tumour size
and nodal status.
The presence and severity of comorbidity was assessed by the
use of the Index of Co-existent Diseases, an established
standardised index of comorbidity (Greenfield et al, 1987).
Socioeconomic status was derived from a patient’s postcode and
grouped according to the Carstairs Index (Carstairs and Morris,
1991). Cause of death was determined from the original death
certificates. Breast cancer-specific mortality was used in analysis of
survival. Data on follow-up were available until the end of 1996.
Average follow-up was 8 years and thus 8-year follow-up is
reported.
Definitions of specialist units
Our aim was to determine whether the previously demonstrated
variation in survival between women treated by specialists and
nonspecialists was related to clinical management. Thus, we kept
the original classification of specialists – those with characteristics
of a multidisciplinary meeting, keeping their own records, a
defined relationship with a named oncologist and pathologist, and
participation in clinical trials. All surgeons had equal access to the
same regional centre for oncology.
Definitions of adequacy of treatment
The clinical management of breast cancer has progressed from the
time studied. Therefore, it was necessary to apply an independent
standard of adequate local and regional treatment contemporary
with the study period. The Kings’ Fund Consensus Statement
(King’s Fund Forum Consensus Statement, 1986) was published at
the beginning of the study and was chosen as a standard, against
which treatment could be compared. Treatment was thus
categorised as adequate or inadequate. Only treatment deemed
by this standard as inadequate is considered, as we were primarily
concerned with factors that could adversely affect recurrence.
Changes in treatment which were previously considered as
excessive, for example radiotherapy after mastectomy, may now
be considered as appropriate and are therefore not reported.
Where treatment varied from the Kings’ Fund Guidelines, a search
was made for evidence of patient choice. Excluded from the
comparison of adequacy of treatment were women who chose
treatment not recommended in the guidelines and women involved
in clinical trials of local treatment (99 women treated in specialist
units compromising 10.9% of the total treated, and 19 in
nonspecialist units, 1.5% of the total treated).
Treatment of the breast was considered inadequate if breast-
conserving surgery was performed for tumours larger than 30mm,
or if resection margins were positive, or if radiotherapy was
omitted. Axillary staging was considered inadequate if no
procedure was performed or if less than four negative nodes were
obtained on an axillary sample. Axillary treatment was considered
inadequate if further treatment (surgery or radiotherapy) was
omitted after an inadequate staging procedure, or a positive
axillary sample.
Statistical analysis
The validity of the data set was substantiated by demonstrating the
expected distribution of patient factors (age, menopausal status)
and pathological factors (size, nodal status, histological prognostic
grade), and confirming the recognised impact of these pathological
and treatment factors (use of radiotherapy and endocrine therapy)
on local recurrence and survival.
The case-mix of specialists and nonspecialists was compared
using the w
2-test of association (Table 1). The definitions of
adequacy of treatment were confirmed as being valid independent
of other prognostic factors (tumour size, histological prognostic
group and nodal status) by comparing the relative hazard ratio
(RHR) of recurrence for inadequate compared to adequate
Table 1 The case-mix of operable breast cancers treated by specialists
and nonspecialists
Specialist units Nonspecialists
Number (%) Number (%) P-value
Tumour size
0–19mm 362 43.4 363 32.7
20–39mm 356 42.7 546 49.2
40+mm 116 13.9 201 18.1 o0.001
Not stated 72 132
Average size (mm) 22.5 25.9
Nodal status
Negative 470 56.4 508 54.1
Positive 363 43.6 431 45.9 0.339
Unknown 73 303
Oestrogen receptor status
Negative 307 41.6 352 46.7
Positive 431 58.4 401 53.3 0.048
Unknown 168 489
Histological prognostic group
Good 180 24.7 114 22.3
Moderate 372 51.0 153 29.9
Poor 178 24.4 244 47.7 o0.001
Not stated 176 731
Menopausal Status
Premenopausal 238 26.3 326 26.2
Postmenopausal 668 73.7 916 73.8 1.000
Deprivation category
1, 2 268 29.6 237 19.1
3–5 355 39.2 570 45.9
6, 7 283 31.2 435 35.0 o0.001
Comorbidity
Incidence of FS/IDV 40 260 28.7 386 31.1 0.253
Mean IDV 1.3 1.1
Mean FS 1.0 1.0
Mean age 56.0 710.3 56.9 710.9 0.067
Italics refers to ‘not stated’ or ‘unknown’ categories and are not included in the
calculation of %.
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ltreatment on multivariate analysis using Cox’s proportional
hazards model (Table 2). The rate and adequacy of performing
breast-conserving surgery, axillary staging and definitive axillary
treatment were compared between specialists and nonspecialists
(Table 3). The 8-year breast and axillary recurrence rates were
calculated using the Kaplan–Meier estimates. The RHR of
recurrence comparing specialists and nonspecialists was calculated
with tumour size, nodal status and histological prognostic group as
independent variables. The rate of prescription of systemic therapy
(endocrine therapy or chemotherapy) was compared between
specialists and nonspecialists in premenopausal and postmeno-
pausal women separately, and particularly in those with tumours
of poor prognosis (larger than 40mm, node positive, and poor
histological prognostic group). The RHR of death was calculated
on univariate analysis for the following variables: patient factors
(age, deprivation category), pathological factors (tumour size,
nodal status, histological prognostic group) and treatment factors
(use of endocrine therapy, chemotherapy, after a local recurrence)
and by speciality of treating surgeon (Table 4). To allow an
appreciation of the relative influence of these various factors, a
multivariate analysis of the RHR of death comparing nonspecia-
lists to specialists was calculated with all factors except local
recurrence included stepwise as independent variables. This
multivariate analysis was lastly repeated including all the above
plus local recurrence as independent variables. To further confirm
the relationship between local recurrence and death, we calculated
the correlation coefficient of the RHR of recurrence against the
RHR of death for each of the separate hospitals, using the best unit
as baseline.
RESULTS
Case-mix
The incidence of locally advanced tumours at presentation was
similar in specialist (116 out of 1022¼11.4%) and nonspecialist
(147 out of 1389¼10.6%) units (P¼0.553). Among the 906
Table 2 Definitions of adequacy of breast and axillary treatment and the risk of recurrence
Treatment of the breast
Adequacy Definition RHR recurrence
a
Adequate Mastectomy 1.00
Conservation: size o 30mm+margins clear+RT
Inadequate Conservation: size 430mm/margins positive/no RT 2.98
(2.30–3.88)
Treatment of the axilla
Adequacy Definition RHR recurrence
a
Adequate Axillary clearance/sample of 4+ negative nodes 1.00
Axillary radiotherapy: after sampling or no surgery
Inadequate Axillary sample only (o4 or positive nodes) 2.29
No axillary procedure (1.65–3.16)
aAfter adjustment for nodal status, tumour size and histological prognostic group. Both P-values o0.001.
Table 3 Specialist and nonspecialist treatment of the axilla and breast, adequacy of treatment and relative risk of recurrence
Specialists Nonspecialists
No. % No. % P-value
Treatment of the Breast
Conservation Surgery 462/906 51.0 572/1242 46.1 0.026
Inadequate conservation 104 22.5 285 49.8 o0.001
Local recurrence rate
a 7% 14% o0.001
RHR local recurrence
b 1.00 1.54 o0.001
(1.10–2.20)
Staging of the axilla
Rate of axillary staging 843/906 93.0 984/1242 79.2 o0.001
Inadequate staging 69/906 7.6 503/1242 40.5 o0.001
Treatment of the axilla
Inadequate treatment 40/906 4.4 468/1242 37.7 o0.001
Axillary recurrence rate
a 6% 11% o0.001
RHR axillary recurrence
b 1.00 2.06 o0.001
(1.48–2.88)
Systemic treatment
Premenopausal women
Chemotherapy (CT) rate 72/238 30.3 49/326 15.0 o0.001
Endocrine therapy (ET) rate 102/238 42.9 170/326 52.1 0.033
CT or ET in prognostically poor
c 84/101 83.2 98/127 77.2 0.320
Postmenopausal women
Endocrine therapy rate 518/668 77.5 723/916 78.9 0.537
CT or ET in prognostically poor
c 241/282 85.5 276/332 83.1 0.440
aActuarial estimate at 8 years.
bAfter adjustment for nodal status, tumour size and histological prognostic grade.
cTumours greater than 40mm, node positive or poor histological
prognostic group.
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treated by nonspecialists, there was no significant difference in
mean age; menopausal status; incidence and severity of comor-
bidity and nodal status (Table 1). The distributions of tumour size,
histological prognostic group, deprivation category and oestrogen
receptor status were significantly different. Nonspecialists treated
women with slightly larger tumours, who were more frequently in
a lower deprivation category, less frequently oestrogen receptor
positive and more frequently had a poorer prognostic tumour.
However, pathological stage was less completely reported in
nonspecialist units; data were more often unobtainable on tumour
size (8 vs 24%), grade (20 vs 61%), oestrogen receptor status (18 vs
38%) and axillary nodal status (7 vs 21% had no staging
procedure).
Diagnosis
Preoperatively, a histological diagnosis was more often obtained by
specialists (81 vs 33%, Po0.001), and consequently excisional
biopsy was used more frequently by nonspecialists (18 vs 67%,
Po0.001). Mammography was also performed more frequently by
specialist units (71 vs 38%, Po0.001).
Confirmation of definition of adequacy as independent
predictor of recurrence
In the breast or axilla, the risk of recurrence on univariate analysis
was significantly higher as size increased, for node positive
compared to node negative tumours, for histological prognostic
group (RHR for groups: good¼1 (baseline); moderate¼2.55.
(1.6–4.08); poor¼5.19 (3.3–8.15), Po0.001) and for ‘inadequate’
compared to ‘adequate’ treatment (Table 2). On multivariate
analysis, the RHR of breast and axillary recurrence remained
significantly higher if treatment was ‘inadequate’ after including
histological prognostic group, nodal status and tumour size as
independent variables (RHR¼2.98 and 2.29, Po0.001). This
confirmed the validity of the definition of adequacy of treatment
as an important independent predictor of recurrence.
Treatment of the breast
Nonspecialists performed breast-conserving surgery less fre-
quently than specialists (Table 3). Overall, inadequate breast-
conserving surgery was performed twice as frequently by
nonspecialists compared to specialists (23 vs 50%, Po0.001).
Nonspecialists performed conservation surgery more frequently
for tumours greater than 30mm (4 vs 16%, Po0.01), left positive
margins after excision (4 vs 12%, Po0.01), and omitted radio-
therapy more often (16 vs 31%, Po0.01). In addition, data were
often incomplete for women treated by nonspecialists (tumour size
unreported in 24%, margins not specified in 42%). Specialists
performed further surgery when the margins were reported as
positive more frequently than nonspecialists (17 vs 9%, Po0.01).
Specialists omitted radiotherapy after conservation surgery more
selectively – excluding tumours with an excellent prognosis (node
negative, size o10mm, good prognostic group), specialists
omitted radiotherapy after conservation surgery in 8% compared
to 21% by nonspecialists (Po0.001).
Staging and treatment of the axilla
The management of the axilla varied greatly between specialists
and nonspecialists (Table 3, Po0.001. for all results). Axillary
staging was more frequently omitted by nonspecialists (7 vs 21%),
and was inadequate in half of those in whom it was attempted (503
out of 984, 51%). Likewise, definitive treatment of the axilla with
surgery or radiotherapy was more frequently inadequate (4 vs 38%,
Po0.001).
Systemic treatment
In premenopausal women, specialists prescribed endocrine
therapy less frequently (43 vs 52%, P¼0.033), but prescribed
chemotherapy twice as frequently as nonspecialists (30 vs 15%,
P¼0.001, Table 3). In those women with very poor prognostic
tumours, who would maximally gain from systemic treatment,
there was a 6% difference in the prescription of systemic therapy
(17 vs 23% did not receive any additional treatment). In
postmenopausal women, there was no difference in the rates of
prescription of systemic therapy overall (78 vs 79%, P¼ns), and
also in those with poor prognosis. Overall, adjuvant systemic
therapy was prescribed equally by specialists and nonspecialists
(692 out of 906, 76% vs 942 out of 1242, 76%, P¼ns).
Recurrence rates
The local and regional recurrence rates were compared between
specialists and nonspecialists (Table 3, 8-year rates and Po0.001
for all results). The ipsilateral breast recurrence rates of
nonspecialists were double that of specialists (7 vs 14%,
RHR¼1.54). The axillary recurrence rates for nonspecialists were
double that of specialists (6 vs 11%, RHR¼2.06). The overall first
locoregional (local or axillary) recurrence rate of nonspecialists
was double that of specialists (13 vs 23%, RHR¼1.59).
Survival
The unadjusted relative risk of death from breast cancer was
calculated on univariate analysis for speciality of treating surgeon
(RHR¼1.37, Po0.001, Table 4), case-mix, pathological factors,
postoperative therapies, and after a local recurrence (RHR 3.42,
Po0.0001). The RHR of death comparing nonspecialists to
specialists was then calculated by adjusting for other factors in a
stepwise mutlifactorial analysis: case-mix (RHR 1.35, Po0.001),
pathological stage (RHR¼1.28, Po0.05), adjuvant treatment
(RHR¼1.27, Po0.05). None of these factors fully accounted for
the survival differences seen. To try and explain this difference, we
included the adequacy of locoregional treatment. After including
Table 4 The relative hazard ratio of death comparing specialist and nonspecialists
Specialists Nonspecialists
(baseline) (RHR, 95% CI) P-value
Unadjusted 1.00 1.37 (1.16–1.61) o0.001
Adjusted for case mix
a 1.00 1.35 (1.14–1.6) o0.001
Adjusted for case mix
a, pathology
a 1.00 1.28 (1.01–1.49) 0.034
Adjusted for case mix
a, pathology
a Treatment
a 1.00 1.27 (1.04–1.55) 0.026
Adjusted for case mix
a, pathology
a, treatment
a+adequacy
a 1.00 1.16 (0.97–1.39) 0.103
aIndependent variables: case-mix: deprivation category, age; pathology: tumour size, nodal status, histological prognostic group; treatment: endocrine therapy, chemotherapy;
adequacy: adequacy of locoregional treatment.
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relative risk of death was 1.16 (0.97–1.39), (P¼0.1), thus implying
that the cause of the better survival of women treated by specialists
was related to better local control of disease.
This relationship was confirmed by correlating the RHR of
locoregional recurrence against the RHR of death across the nine
treating hospitals using the hospital with the best outcome as a
baseline. There was a strong correlation between the risk of
locoregional recurrence and death (R
2¼0.69). There was only a
poor correlation between adequacy of treatment and caseload
(R
2¼0.24).
DISCUSSION
This study is the most detailed and complete analysis of treatment
delivered with sufficient follow-up to allow an understanding of
the reasons behind variability in survival. We have demonstrated
that adequacy of surgical management is an important indepen-
dent risk factor for locoregional recurrence, and that the survival
of women treated by surgeons with a lower locoregional recurrence
rate is correspondingly better. This was independent of case-mix,
prognostic pathological factors and adjuvant therapies. In
specialist units during the time period studied, there was half the
risk of inadequate treatment of the breast (24 vs 47%), one-fifth of
the risk of inadequate axillary staging (8 vs 40%) and one-ninth of
the risk of inadequate definitive axillary treatment (4 vs 38%). This
is reflected in recurrence rates that are halved (7 vs 14% after
breast-conserving treatment and 6 vs 11% in the axilla) and a 20%
lower risk of death from breast cancer.
Our primary conclusion is that adequate surgical management is
of underlying fundamental importance to the improvement in
survival demonstrated by specialist surgeons. Categorisation using
proxy measures of specialisation, such as hospital type, location,
size, association with teaching facilities, caseload and selection,
deflects attention away from the process of appropriate and
adequate care to the structure of care delivery. However, local and
regional recurrence only partly explained the associated increased
risk of mortality (a halving of the relative risk of mortality in
Table 4). Thus, we believe that the adequacy and appropriateness
of all treatments is the key to explaining improvements in survival
outcomes.
This study examined the case-records of 95% (2780 out of 2934)
of all women treated for breast cancer during this time period. The
completeness of identifying cases was verified from five indepen-
dent sources; the cancer registry, the NHS Breast Screening service,
a dedicated breast cancer regional pathology database, personal
records of individual surgeons and two hospitals which held their
own separate records. All data were retrieved from original case
records by a surgically trained investigator (DBK) and accuracy
checked by comparison with a database derived separately from
pathology reports and case-records from the regional centre for
oncology. The validity of the data set was confirmed both by
internal checks (distribution patterns, correlation tumour size with
nodal status and histological prognostic grouping, and impact of
these pathological factors and treatment factors on recurrence and
survival) and external comparisons. Thus, we are confident that
the data is complete, accurate, and has been correctly interpreted.
Accurate pathological data was less often complete for women
treated in nonspecialist units (Table 1). This was due to several
factors such as the omission to surgically stage (e.g. the axilla) and
the use of excisional biopsy as the method of tissue diagnosis (e.g.
thus tumour size and margin status were not reported). We do not
believe that the variability in staging alters our conclusions for the
following reasons: firstly, we have already shown that the
improvement in survival associated with specialist care cannot
be due to case-mix (Gillis and Hole, 1996). Secondly, the criteria
used to define inadequate treatment rely on pathological data
where this is reported, thus missing information can only
underestimate the true occurrence of inadequate treatment, for
example excision margins were only reported in 58% of women
with conservation surgery performed by nonspecialists and of
these, one-fifth were positive. Thirdly, we have confirmed that our
definitions of adequacy and inadequacy are strong independent
factors for recurrence independent of pathology (Table 2). Thus,
we do not feel that the lack of complete pathological prognostic
factors renders these results void, but may illustrate the lack of
importance placed upon them by those treating the patients. This
also reflects the considerable debate regarding the place of surgery
in the treatment of breast cancer that was prevalent at that time
period.
Evidence that poorer local treatment and thus local recurrence
may have contributed to poorer survival is presented in two forms;
firstly using a Cox’s proportional hazards model, the relative risk
of dying when treated by a nonspecialist compared to a specialist
remains significantly higher after inclusion of all variables
(RHR¼1.27), but is reduced when adequacy of local treatment
is also included as an independent variable (RHR¼1.16).
Secondly, there is a strong correlation between the risk of death
from breast cancer and the risk of local recurrence when plotted
for each treating hospital (R
2¼0.69). Whilst these two associations
are not proof that locoregional recurrence can disseminate, when
taken in association with the failure of other factors to adequately
account for the variation in survival between units, they do suggest
that inadequate surgical treatment results in locoregional recur-
rence that in turn, may disseminate. These results are consistent
with recently published randomised trials of postmastectomy
radiotherapy in high-risk women that demonstrated increased
locoregional recurrence rates and a subsequently poorer survival
in women who did not receive radiotherapy (Overgaard et al, 1997;
Ragaz et al, 1997).
Variation in diagnostic and therapeutic modalities has been
demonstrated in many previous studies (Greenfield et al, 1987;
Carstairs and Morris, 1991; McCarthy and Bore, 1991; Basnett et al,
1992; Chouillet et al, 1994; Lee-Feldstein et al, 1994; Sainsbury et al,
1995a,b; Overgaard et al, 1997; Ragaz et al, 1997). Difficulties
encountered in these studies included indirect analysis of case-
records by nonsurgical staff, small numbers, incomplete analysis,
limited follow-up and no measurement of outcomes. Several other
surrogate measures of specialisation used in these studies have not
been confirmed in this study. For example, although the rate of
breast-conservation surgery in our study was similar, nonspecia-
lists more often performed inappropriate and inadequate surgery.
Similarly, chemotherapy and endocrine therapy have been used to
compare treatment. In our study, both groups used chemotherapy
infrequently, whereas tamoxifen was used in three-quarters of
women equally. Adjuvant therapies cannot therefore be the cause
of the survival differences seen, and again are poor indicators with
which to compare units. Survival differences have only been
reported in two major observational studies (Gillis and Hole, 1996;
Sainsbury et al, 1995a). Neither of these studies could determine
the exact treatment delivered nor critically, the adequacy of this
and the impact on locoregional recurrence and survival. Despite
these limitations, many guidelines have recommended that
treatment of breast cancer be centralised. This study is the first
to give quantitative evidence that this recommendation is justified.
However, the location of services and designation of ‘specialists’
should not deflect from the fundamental importance of adequate
and appropriate treatment that results in lower locoregional
recurrence rates and improved survival. Indeed, other studies have
found that the implementation of protocols beneficially reduces
variability in treatment (Paci et al, 1994; Winstanley et al, 1995).
Since the period of time studied, there have been great changes to
the organisation and provision of breast cancer treatment with the
implementation of the NHS Breast Screening Programme and the
subsequent Quality Assurance guidelines.
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lCurrent changes in legislature now emphasise quality of care
more than ever. We have demonstrated that clinical effectiveness
and quality can be measured, and the emphasis on measuring
quality of care will benefit patients. With the advent of clinical
governance, future assessment of practice may be based on similar
methodology to that used in this study.
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